306 related articles for article (PubMed ID: 29752605)
1. Influence of incomplete neoadjuvant chemotherapy on esophageal carcinoma.
Fujiwara Y; Lee S; Kishida S; Hashiba R; Gyobu K; Naka R; Nishiyama M; Ihara T; Takemura M; Osugi H
Int J Clin Oncol; 2018 Oct; 23(5):877-885. PubMed ID: 29752605
[TBL] [Abstract][Full Text] [Related]
2. Comparison of neoadjuvant chemotherapy versus upfront surgery with or without chemotherapy for patients with clinical stage III esophageal squamous cell carcinoma.
Matsuda S; Tsubosa Y; Sato H; Takebayashi K; Kawamorita K; Mori K; Niihara M; Tsushima T; Yokota T; Onozawa Y; Yasui H; Takeuchi H; Kitagawa Y
Dis Esophagus; 2017 Feb; 30(2):1-8. PubMed ID: 26919154
[TBL] [Abstract][Full Text] [Related]
3. Investigation of operative outcomes of thoracoscopic esophagectomy after triplet chemotherapy with docetaxel, cisplatin, and 5-fluorouracil for advanced esophageal squamous cell carcinoma.
Akiyama Y; Iwaya T; Endo F; Chiba T; Takahara T; Otsuka K; Nitta H; Koeda K; Mizuno M; Kimura Y; Sasaki A
Surg Endosc; 2018 Jan; 32(1):391-399. PubMed ID: 28664431
[TBL] [Abstract][Full Text] [Related]
4. Prognostic Factors for Esophageal Squamous Cell Carcinoma Treated with Neoadjuvant Docetaxel/Cisplatin/5-Fluorouracil Followed by Surgery.
Sugimura K; Miyata H; Shinno N; Ushigome H; Asukai K; Yanagimoto Y; Hasegawa S; Takahashi Y; Yamada D; Yamamoto K; Nishimura J; Motoori M; Wada H; Takahashi H; Yasui M; Omori T; Ohue M; Yano M
Oncology; 2019; 97(6):348-355. PubMed ID: 31461716
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Advantage of Docetaxel/Cisplatin/ 5-Fluorouracil Neoadjuvant Chemotherapy in Clinical Stage II/III Esophageal Squamous Cell Carcinoma due to Excellent Control of Preoperative Disease and Postoperative Lymph Node Recurrence.
Yamashita K; Hosoda K; Moriya H; Katada C; Sugawara M; Mieno H; Komori S; Katada N; Watanabe M
Oncology; 2017; 92(4):221-228. PubMed ID: 28110330
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-RT) for locally advanced esophageal squamous cell carcinoma.
Sasaki K; Uchikado Y; Omoto I; Arigami T; Osako Y; Noda M; Okumura H; Maemura K; Higashi R; Yoshiura T; Natsugoe S
Cancer Chemother Pharmacol; 2019 Mar; 83(3):581-587. PubMed ID: 30623230
[TBL] [Abstract][Full Text] [Related]
7. Clinical significance of evaluating endoscopic response to neoadjuvant chemotherapy in esophageal squamous cell carcinoma.
Nagai Y; Yoshida N; Baba Y; Harada K; Imai K; Iwatsuki M; Karashima R; Koga Y; Nomoto D; Okadome K; Ishimoto T; Imamura Y; Watanabe M; Baba H
Dig Endosc; 2020 Jan; 32(1):39-48. PubMed ID: 31120560
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant chemotherapy with S-1 plus cisplatin for esophageal squamous cell carcinoma.
Takahashi T; Kaneoka Y; Maeda A; Takayama Y; Seita K
Updates Surg; 2022 Apr; 74(2):675-683. PubMed ID: 34559400
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant chemotherapy of triplet regimens of docetaxel/cisplatin/5-FU (DCF NAC) may improve patient prognosis of cStage II/III esophageal squamous cell carcinoma-propensity score analysis.
Yamashita K; Katada N; Moriya H; Hosoda K; Mieno H; Katada C; Koizumi W; Hoshi K; Watanabe M
Gen Thorac Cardiovasc Surg; 2016 Apr; 64(4):209-15. PubMed ID: 26868531
[TBL] [Abstract][Full Text] [Related]
10. Long-term outcomes and safety of radical transmediastinal esophagectomy with preoperative docetaxel, cisplatin, and 5-fluorouracil combination chemotherapy for locally advanced squamous cell carcinoma of the thoracic esophagus.
Yamagata Y; Saito K; Hirano K; Oya M
World J Surg Oncol; 2020 Sep; 18(1):252. PubMed ID: 32962718
[TBL] [Abstract][Full Text] [Related]
11. Simple Cancer Stem Cell Markers Predict Neoadjuvant Chemotherapy Resistance of Esophageal Squamous Cell Carcinoma.
Agawa K; Yamashita K; Nakagawa A; Yamada K; Watanabe A; Mukohyama J; Saito M; Fujita M; Takiguchi G; Urakawa N; Hasegawa H; Kanaji S; Matsuda T; Oshikiri T; Nakamura T; Suzuki S; Kakeji Y
Anticancer Res; 2021 Aug; 41(8):4117-4126. PubMed ID: 34281882
[TBL] [Abstract][Full Text] [Related]
12. Clinical Significance of Prealbumin Level Measurement Before Neoadjuvant Chemotherapy in Elderly Patients With Locally Advanced Esophageal Cancer.
Suematsu H; Yamada T; Onuma S; Hashimoto I; Kanematsu K; Nagasawa S; Aoyama T; Ogata T; Rino Y; Saito A; Oshima T
In Vivo; 2024; 38(1):334-340. PubMed ID: 38148082
[TBL] [Abstract][Full Text] [Related]
13. First-line chemotherapy improves the resection rate and long-term survival of locally advanced (T4, any N, M0) squamous cell carcinoma of the thoracic esophagus: final report on 163 consecutive patients with 5-year follow-up.
Ancona E; Ruol A; Castoro C; Chiarion-Sileni V; Merigliano S; Santi S; Bonavina L; Peracchia A
Ann Surg; 1997 Dec; 226(6):714-23; discussion 723-4. PubMed ID: 9409570
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant chemotherapy with irinotecan and nedaplatin in a single cycle followed by esophagectomy on cT4 resectable esophageal squamous cell carcinoma: a prospective nonrandomized trial for short-term outcomes.
Tian D; Zhang L; Wang Y; Chen L; Zhang KP; Zhou Y; Wen HY; Fu MY
Dis Esophagus; 2019 Mar; 32(3):. PubMed ID: 30247659
[TBL] [Abstract][Full Text] [Related]
15. Effect of Time to Minimally Invasive Esophagectomy After Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma.
Loc NVV; Vuong NL; Trung LV; Trung TT
J Gastrointest Cancer; 2023 Dec; 54(4):1240-1251. PubMed ID: 36723785
[TBL] [Abstract][Full Text] [Related]
16. The prognostic significance of the positive circumferential resection margin in pathologic T3 squamous cell carcinoma of the esophagus with or without neoadjuvant chemotherapy.
Okada N; Fujii S; Fujita T; Kanamori J; Kojima T; Hayashi R; Daiko H
Surgery; 2016 Feb; 159(2):441-50. PubMed ID: 26391150
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant versus adjuvant chemoradiation for stage II-III esophageal squamous cell carcinoma: a single institution experience.
Chen Y; Hao D; Wu X; Xing W; Yang Y; He C; Wang W; Liu J; Wang J
Dis Esophagus; 2017 Jul; 30(7):1-7. PubMed ID: 28475725
[TBL] [Abstract][Full Text] [Related]
18. Toripalimab Plus Paclitaxel and Carboplatin as Neoadjuvant Therapy in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma.
He W; Leng X; Mao T; Luo X; Zhou L; Yan J; Peng L; Fang Q; Liu G; Wei X; Wang K; Wang C; Zhang S; Zhang X; Shen X; Huang D; Yi H; Bei T; She X; Xiao W; Han Y
Oncologist; 2022 Feb; 27(1):e18-e28. PubMed ID: 35305102
[TBL] [Abstract][Full Text] [Related]
19. Survival outcomes of neoadjuvant immunochemotherapy versus chemotherapy for locally advanced esophageal squamous cell carcinoma.
Lv H; Zhang F; Huang C; Xu S; Li J; Sun B; Gai C; Liu Z; Wang M; Li Z; Tian Z
J Cancer Res Clin Oncol; 2024 May; 150(5):260. PubMed ID: 38760614
[TBL] [Abstract][Full Text] [Related]
20. Docetaxel+Cisplatin+5-FU (DCF) Therapy as a Preoperative Chemotherapy to Advanced Esophageal Squamous Cell Carcinoma: A Single-center Retrospective Cohort Study.
Umeki Y; Matsuoka H; Fujita M; Goto A; Serizawa A; Nakamura K; Akimoto S; Nakauchi M; Tanaka T; Shibasaki S; Inaba K; Uyama I; Suda K
Intern Med; 2023; 62(3):319-325. PubMed ID: 36725064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
